Skip to content
Medical Health Aged Care

New drug could be answer to an overlooked yet devastating type of dementia

Monash University 2 mins read

Monash University researchers are assessing a new drug that could be a game changer for the dementia that has struck US actor Bruce Willis, and countless others as young as 35: behavioural variant frontotemporal dementia (bvFTD). 

 

Unlike other types of dementia, such as Alzheimer’s Disease, there are no treatments; but a new drug — sodium selenate — was shown to be safe and well tolerated in people living with bvFTD, as outlined in the team’s 2022 study

 

Now, the team is announcing the next step: measuring the drug’s impact on brain functioning. 

 

While relatively rare, FTD causes progressive damage and shrinkage to either or both the frontal or temporal lobes of the brain, along with behavioural changes such as impulsivity, inappropriate behaviour and emotional indifference, and loss of language. 

 

Neuroscientists Professor Terence O’Brien and Dr Lucy Vivash, from the School of Translational Medicine, are leading a phase 2b clinical trial in which half the participants will receive 52 weeks of treatment with sodium selenate, and the other half a placebo.

 

"This is an internationally unique clinical trial that, if positive, would bring to patients the first proven disease-modifying treatment for this currently untreatable and devastating progressive neurodegenerative disease,” Professor O’Brien said.    

 

“It’s also an inexpensive drug, which is important, as we’ve seen recently that new promising treatments for dementias can cost much more than what governments and ordinary people can afford. Sodium selenate is not quite as cheap as aspirin, but it is unlikely to cost tens of thousands of dollars either.”

 

Colleague Professor Amy Brodtmann, from the School of Translational Medicine, said while it is generally difficult to recruit patients with degenerative neurological conditions, FTD posed even more challenges. “Fronto-temporal dementia is often misdiagnosed as depression, anxiety or Alzheimer’s Disease,” she said. 

 

“Carers or partners are often exhausted from navigating the health system for a correct diagnosis, as GPs tend not to think of dementia when the person in front of them is in their 30s, 40s or 50s.” 

 

Over the 52 weeks of the trial, the team will compare changes to brain volume in the  treatment and placebo groups. They’ll also look at the levels of tau, a protein involved in the development of FTD in the cerebrospinal fluid, the rate of cognitive decline, and behavioural changes.

 

The 12-month trial needs 120 participants, aged 35 years and older with a diagnosis of possible or probable bvFTD. Participation will involve cognitive tests, brain scans and regular phone check-ins. 

 

To find out more and express interest in joining the trial: 

Email: selenate@alfred.org.au  

Website: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=379271 

Telephone: 03 9903 0121

 

To find out more about sodium selenate and bvFTD, please visit: https://www.facebook.com/SodiumSelenate/ 

 

- ENDS -

MEDIA ENQUIRIES 

Helena Powell

Media Communications Officer, Monash University 

M: +61 474 444 171

E: helena.powell@monash.edu 

 

GENERAL MEDIA ENQUIRIES

Monash Media

T: +61 (0) 3 9903 4840

E: media@monash.edu

For more Monash media stories, visit our news and events site 

More from this category

  • Medical Health Aged Care, Science
  • 05/11/2024
  • 07:00
UNSW Sydney

Scientists develop test to better track whooping cough strains amid national outbreak

Used to analyse past outbreaks, the new method could be implemented to inform public health policy. Researchers at UNSW Sydney and the University of…

  • Contains:
  • Government NSW, Medical Health Aged Care
  • 04/11/2024
  • 14:58
Uniting NSW.ACT

*** MEDIA ALERT *** Uniting NSW.ACT available for comment after Drug Summit in Lismore today

*** MEDIA ALERT *** Uniting NSW.ACT’s General Manager of Advocacy & External Relations Emma Maiden is available for comment following the NSW Drug Summit in Lismore today: Speaking after this morning’s session, she said: “Many of the issues outlined by those who attended day one of the drug summit in Griffith are being echoed by the people from Lismore and the NSW Northern Rivers region speaking on day two. “They have reflected on the ongoing trauma being felt right across their community and on how many have either started or returned to using drugs as a way to deal with…

  • Medical Health Aged Care
  • 04/11/2024
  • 09:00
Dementia Australia

Dementia Australia supports Mackay, Isaac and Whitsunday region

Are you concerned about your memory or worried that someone you know may have dementia? Dementia Australia is offering support in Mackay, Isaac and Whitsunday region between 18 and 22 November. It is estimated there around 82,270 people living with all forms of dementia in Queensland. Without a medical breakthrough this number is expected to increase to around 168,300 people living with dementia by 2054. These Dementia Australia sessions are an opportunity for people living with dementia, their carers, family, and friends to attend free education to better understand dementia and to discuss the support and services Dementia Australia can…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.